Yüksel Ürün/X
Mar 8, 2025, 09:01
Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X about recent paper by Anwen Xiong et al., titled “Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China” published on The Lancet.
Authors: Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu, Baogang Liu, Jun Yao, Hua Zhong, Jie Li, Ying Cheng, Yulan Sun, Hui Ge, Jifang Yao, Qin Shi, Ming Zhou, Bolin Chen, Zhengxiang Han, Jinliang Wang, Qing Bu, Yanqiu Zhao, Junqiang Chen, Caicun Zhou
“New study alert!
Ivonescimab hit 11.1m PFS vs 5.8m with pembrolizumab in PD-L1+ NSCLC. Promisin results that might shift treatment options!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 17:03
Jun 8, 2025, 16:53